biologic

Xenpozyme

olipudase alfa-rpcp

Loss of exclusivityMarch 2035projected — 12-year biologic exclusivity estimate
CompanyGenzyme Corporation

Drug detail

Brand nameXenpozyme
Active ingredientolipudase alfa-rpcp
Strength4MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2023
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Xenpozyme patent cliff — loss of exclusivity March 2035 | CliffBio